Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Cash from Investing Activities (2018 - 2019)

DiaMedica Therapeutics (DMAC) has 2 years of Cash from Investing Activities data on record, last reported at $1.0 million in Q4 2019.

  • For Q4 2019, Cash from Investing Activities rose 7653.85% year-over-year to $1.0 million; the TTM value through Dec 2019 reached -$3.9 million, down 7716.0%, while the annual FY2024 figure was $8.6 million, 146.8% up from the prior year.
  • Cash from Investing Activities reached $1.0 million in Q4 2019 per DMAC's latest filing, down from $3.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $3.0 million in Q2 2019 and bottomed at -$10.9 million in Q1 2019.